Graphene could strip polluting medicines from wastewater

By Phil Taylor

- Last updated on GMT

Graphene could strip polluting medicines from wastewater

Related tags Water Sewage treatment

Pollution caused by pharmaceuticals in wastewater is a major challenge facing the industry, but researchers in Greece may have come up with a solution.

The team from the Aristotle University of Thessaloniki have shown that graphene - a wonder material made up of sheets of carbon a single atom thick - can remove drugs that current wastewater treatment technologies cannot handle.

Pharmaceuticals are often excreted from the human body with little or no changes to their chemical structure, finding their way into wastewater and even in some cases drinking water supplies, according to the scientists.

A lot of the environmental concerns surrounding drugs in the environment centre around antibiotics​ and their potential to affect wildlife and precipitate antibiotic resistance, an issue which sparked protests​ at the this year's CPhI conference in Madrid. 

There are a number of other drug classes that are challenging to remove and have environmental consequences, however, including beta blockers that have been shown to affect the life cycles of aquatic algae, plants and insects.

Using graphene oxide (GhO) as an adsorbent material within wastewater treatment plants, the researchers were able to show that two common beta blockers - atenolol and propranolol - could be removed effectively in a manner compatible with existing processes. 

Importantly, the GhO could also be recycled and re-used, which could keep costs down, they note. The research is published​ in the journal Science of the Total Environment​ (15 December 2015).

Graphene is one of the thinnest and strongest materials known and is already finding applications in drug and gene delivery, biosensors and prosthetics, as well as a host of uses in materials science outside the pharma sector. 

Seeking to tap into its potential, the UK recently formed a £60m ($95m) National Graphene Institute (NGI) based at the University of Manchester to provide a single hub for research into the substance.

The Green Lobby

In addition to tackling pollution of excreted drugs, the pharma industry has also come under fire from the green lobby for the release of environmentally-damaging compounds into water systems as a consequence of API production.

Three drug substances - two oestrogen hormones and an anti-inflammatory drug (diclofenac) - were added to an EU 'watch list'​ of possible surface water pollutants in 2013, the first time pharma compounds had been added to the monitoring list. Industry lobbying prevented them from being added to a priority list that would have introduced stricter controls.

It is feasible that graphene could also be applied within facilities to clean up effluent, although this was not addressed in the current study. 

Some API producers - including DSM-Sinochem and GlaxoSmithKline​ - are taking other efforts to introduce processes that reduce the environmental impact of their operations, for example by limiting the release of toxic chemicals from facilities and phasing out the use of organic solvents.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us


View more